Free radical scavenger edaravone produces robust neuroprotection in a rat model of spinal cord injury.
Brain Res
; 1682: 24-35, 2018 03 01.
Article
em En
| MEDLINE
| ID: mdl-29294349
ABSTRACT
We used a multimodal approach to evaluate the effects of edaravone in a rat model of spinal cord injury (SCI). SCI was induced by extradural compression of thoracic spinal cord. In experiment 1, 30â¯min prior to compression, rats received a 3â¯mg/kg intravenous bolus of edaravone followed by a maintenance infusion of 1 (low-dose), 3 (moderate-dose), or 10 (high-dose) mg/kg/h edaravone. Although both moderate- and high-dose edaravone regimens promoted recovery of spinal motor-evoked potentials (MEPs) at 2â¯h post-SCI, the effect of the moderate dose was more pronounced. In experiment 2, moderate-dose edaravone was administered 30â¯min prior to compression, at the start of compression, or 10â¯min after decompression. Although both preemptive and coincident administration resulted in significantly improved spinal MEPs at 2â¯h post-SCI, the effect of preemptive administration was more pronounced. A moderate dose of edaravone resulted in significant attenuation of lipid peroxidation, as evidenced by lower concentrations of the free radical malonyldialdehyde in the spinal cord 3â¯h post-SCI. Malonyldialdehyde levels in the high-dose edaravone group were not reduced. Both moderate- and high-dose edaravone resulted in significant functional improvements, evidenced by better Basso-Beattie-Bresnahan (BBB) scores and better performance on an inclined plane during an 8â¯week period post-SCI. Both moderate- and high-dose edaravone significantly attenuated neuronal loss in the spinal cord at 8â¯weeks post-SCI, as evidenced by quantitative immunohistochemical analysis of NeuN-positive cells. In conclusion, early administration of a moderate dose of edaravone minimized the negative consequences of SCI and facilitated functional recovery.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Traumatismos da Medula Espinal
/
Antipirina
/
Fármacos Neuroprotetores
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Brain Res
Ano de publicação:
2018
Tipo de documento:
Article